INFU Filings — Infusystem Holdings, Inc. - FilingSpy
INFU
Infusystem Holdings, Inc.
A company that rents, sells, and services ambulatory infusion pumps and the disposable supplies used to receive continuous chemotherapy, delivering them to patients at home or in oncology clinics. Founded in 1999 in Rochester Hills, Michigan, it became a public company in 2007 when a public acquirer bought the business from its former parent, I-Flow Corporation. Its portable pumps let patients carry chemotherapy in a small bag and go about daily life rather than staying in a hospital bed.
Device Solutions margin hit 50.2% as a restructured contract lifted profitability, even while segment revenue fell 16%.
The Device Solutions turned a corner on profitability. rose 2.6% to $36.9 million and climbed 24% to $3.2 million, as a restructured biomedical contract and favorable sales mix pushed Device Solutions to 50.2%, more than offsetting a 16% revenue decline in that segment. The company is now more profitable on a lower Device Solutions revenue base, while Patient Services volume growth continues.
Key takeaways
Device Solutions rose 8.3 points to 50.2%, its highest level in the series, driven by lower contract costs under the restructured GE Healthcare biomedical services agreement and a favorable mix shift toward higher-margin equipment sales and rentals.
Patient Services rose 15.2% to $24.8 million on higher Oncology and Wound Care treatment volumes, though its fell 2.4 points to 61.8% as growth in lower-margin Wound Care revenue, including new compression therapy device sales, shifted the 's mix.
Section summaries
Management's Discussion and Analysis
Q2 2026 net income rose 24% to $3.2M on 2.6% revenue growth, driven by Patient Services volume and Device Solutions margin expansion.
⌄
Total net revenues increased 2.6% to $36.9M, as a 15.2% jump in Patient Services ($24.8M) from higher Oncology and Wound Care volumes offset a 16.1% decline in Device Solutions ($12.1M).
Wound Care surged 154% to $2.1M, fueled by new Pneumatic Compression Device and Adjustable Compression Wrap supplier relationships launched in late 2025 and early 2026.
Wound Care rose 154% to $2.1 million, fueled by new supplier relationships for Pneumatic Compression Devices and Adjustable Compression Wraps launched in late 2025 and early 2026.
Consolidated improved 2.8 points to 58.0%, as the Device Solutions more than offset the Patient Services margin decline.
fell 3.3% to $6.8 million, as a $5.0 million increase in consumption, primarily from higher , more than offset a $4.0 million rise in adjusted .
The Board authorized a new $20 million program effective July 1, 2026, and the company's new ERP system went live on March 1, 2026.
What changed
The prior filing flagged whether Device Solutions could sustain above 40% without one-time items. In Q2 2026, the margin reached 50.2%, up from 41.9% a year ago, driven by the restructured GE Healthcare contract and favorable mix — suggesting the improvement is structural rather than reliant on non-recurring adjustments.
The prior filing asked whether Device Solutions would stabilize after the GE Healthcare restructuring. Revenue fell 16.1% to $12.1 million, as the $1.6 million biomedical services reduction and a $1.0 million drop in equipment sales from a prior-year rental buyout continued to weigh on the top line.
The prior filing questioned whether Patient Services would continue to decline as Wound Care mix shifted. The margin fell another 2.4 points to 61.8%, confirming the trend as Wound Care rose 154%.
The prior filing asked whether would recover from the weak Q1 level of $1.0 million. Cash flow rebounded to $6.8 million in Q2, though it remained 3.3% below the prior-year quarter as consumption persisted.
The material weakness in internal controls over rental contract recognition, flagged in every prior filing, was resolved in the FY2025 annual report with an unqualified audit opinion from Deloitte & Touche on internal controls.
What to watch
Whether Device Solutions can sustain at or above 50% in the second half of FY2026, confirming the GE Healthcare contract restructuring has permanently reset profitability.
The trajectory of Patient Services as Wound Care continues to grow rapidly, and whether the 61.8% Q2 margin represents a floor or if further mix shift will compress it further.
Whether Device Solutions stabilizes after two consecutive quarters of double-digit declines, or if the 's top line resets to a lower base as the biomedical contract restructuring fully annualizes.
The pace and funding of share repurchases under the new $20 million authorization, given the cash balance of $1.0 million and $20.4 million in .
Device Solutions fell due to a $1.6M reduction from a restructured GE Healthcare biomedical services contract and a $1.0M drop in equipment sales tied to a prior-year rental buyout.
Consolidated improved 2.8pp to 58.0%, with Device Solutions margin up 8.3pp to 50.2% on lower contract costs and favorable mix, while Patient Services margin dipped 2.4pp to 61.8% on lower-margin Wound Care mix.
decreased $1.0M to $7.7M as a $5.0M increase in use, mainly from higher , more than offset a $4.0M rise in adjusted .
The Board authorized a new $20M program starting July 1, 2026, and the ERP system went live on March 1, 2026, with related project expenses expected to taper.
We are subject to certain claims and lawsuits in the ordinary course of business, the outcome of which cannot be determined at this time. In the opinion of management, any liability we might incur upon the resolution of these claims and lawsuits will not, in the aggregate, have…
⌄
We are subject to certain claims and lawsuits in the ordinary course of business, the outcome of which cannot be determined at this time. In the opinion of management, any liability we might incur upon the resolution of these claims and lawsuits will not, in the aggregate, have a material adverse effect on our consolidated financial position or results of operations.
For information regarding factors that could affect our results of operations, financial condition and liquidity, refer to the section entitled “Risk Factors” in Part I, Item 1A. in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on Februar…
⌄
For information regarding factors that could affect our results of operations, financial condition and liquidity, refer to the section entitled “Risk Factors” in Part I, Item 1A. in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 27, 2026.